Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.84 +0.31 (+1.80%)

Streaming Delayed Price Updated: 11:31 AM EDT, Jun 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Novavax Stock Down On Concern Over Whether The Company Can Continue ↗

February 28, 2023

Novavax warns that it may not be able to continue as a company.

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

February 28, 2023

Via Benzinga

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Expert Ratings for Sarepta Therapeutics ↗

February 15, 2023

Via Benzinga

9 Analysts Have This to Say About Sarepta Therapeutics ↗

January 20, 2023

Via Benzinga

BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know ↗

December 22, 2022

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

November 03, 2022

Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript ↗

November 03, 2022

SRPT earnings call for the period ending September 30, 2022.

Via The Motley Fool

Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program

February 28, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

7 Analysts Have This to Say About Sarepta Therapeutics ↗

October 13, 2022

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:

Via Benzinga

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results

February 21, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

February 17, 2023

From Sarepta Therapeutics, Inc.

Via Business Wire

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

January 06, 2023

These biotechnology stocks are pushing ahead with promising innovations.

Via The Motley Fool

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

January 05, 2023

From Catalent, Inc.

Via Business Wire

2 Top Healthcare Stocks to Buy for the Long Haul ↗

December 09, 2022

These two companies are just getting started.

Via The Motley Fool

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗

December 02, 2022

The S&P 500 is fighting for its 200-day, a critical level for the uptrend.

Via Investor's Business Daily

Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy ↗

November 28, 2022

Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy.

Via Investor's Business Daily

3 Unstoppable Stocks That Could Double in 5 Years ↗

October 29, 2022

The opportunities for these innovators are tremendous.

Via The Motley Fool

2 Under-the-Radar Biotech Stocks to Buy in 2022 ↗

October 19, 2022

These two drugmakers are growing in prominence.

Via The Motley Fool

Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71% ↗

October 17, 2022

Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.

Via Benzinga

Is Pfizer Stock Still Worth Buying After the Pandemic?

October 12, 2022

Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.

Via MarketBeat

Earnings Scheduled For November 2, 2022 ↗

November 02, 2022

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.

Via Benzinga

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

A Trio of Q3 Winners With Room to Run

September 29, 2022

It's those rare bright spots in a dim market that can be the best places to hide. Here are three Q3 outperformers that still have good upside.

Via MarketBeat

Topics Economy Stocks

PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst ↗

September 28, 2022

Via Benzinga

$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying ↗

September 16, 2022

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.